HVIVO PLC — AGM Information 2018

May 23, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0510P

hVIVO plc

23 May 2018

For immediate release 12.30pm: 23 May 2018

HVIVO PLC

("hVIVO" or the "Company")

Result of Annual General Meeting

hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 23 May 2018, were duly passed.

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	+44 207 756 1300
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	+44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	+44 203 727 1000

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGMFKNDDDBKDPPB